Consensus MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-05-15 pm EDT			5-day change	1st Jan Change
3.090 ^USD	-4.04%		-12.22%	-45.50%

May. 07	MannKind Corporation, Q1 2026 Earnings Call, May 06, 2026
May. 06	Earnings Flash (MNKD) MannKind Corporation Posts Q1 Adjusted Loss $0.02 per Share	MT

Evolution of the Average Target: MannKind Corporation

Evolution of the Target Price: MannKind Corporation

Changes in Analyst Recommendations: MannKind Corporation

42.wc40YZkuBXQcJs0GVr8nCrvL9Uan2sOepkl5JUO-E0s.lapGDuFYXw5LcoZoH4xlOvCltAPwr6epiwAYEDXTWgWonVxRzF9aBm5Qpg~80324764ad9eec0156476ab28b9af22a

Analysts' recommendations: MannKind Corporation

Mar. 05	Wedbush Adjusts Price Target on MannKind to $8 From $10, Maintains Outperform Rating	MT
Feb. 27	RBC Downgrades MannKind to Sector Perform From Outperform, Cuts Price Target to $3.50 From $7.50	MT
Nov. 11	RBC Lowers Price Target on MannKind to $7.50 From $8, Keeps Outperform Rating	MT
Nov. 11	Wedbush Cuts Price Target on MannKind to $10 From $11, Keeps Outperform Rating	MT
25-10-13	MannKind's Supplemental BLA for Diabetes Treatment Afrezza Facing 'Limited Regulatory Risk,' Wedbush Says	MT
25-10-13	MannKind announces US FDA accepts for review its sBLA for inhaled insulin	RE
25-09-05	Oppenheimer Adjusts MannKind Price Target to $15 From $12, Maintains Outperform Rating	MT
25-08-26	RBC Raises Price Target on MannKind to $8 From $7, Keeps Outperform Rating	MT
25-08-07	RBC Cuts Price Target on MannKind to $7 From $8, Keeps Outperform Rating	MT
25-08-06	Biotech firm MannKind's Q2 revenue rises 6%	RE
25-07-23	RBC Cuts Price Target on MannKind to $8 From $10, Keeps Outperform Rating	MT
25-04-10	Mizuho Initiates MannKind at Outperform With $12 Price Target	MT
25-02-10	Wedbush Initiates MannKind at Outperform With $11 Price Target	MT
24-12-20	MannKind Shares Rise After Wells Fargo Begins Coverage	MT
24-12-20	Wells Fargo Initiates Coverage on MannKind With Overweight Rating, $9 Price Target	MT
24-12-19	RBC Upgrades MannKind to Outperform From Sector Perform, Raises Price Target to $10 From $7	MT
24-11-14	Tudor Pickering Holt Downgrades MannKind to Hold From Buy, Adjusts Price Target to $5.50 From $7	MT
24-11-08	RBC Capital Adjusts Price Target on MannKind to $7 From $5, Maintains Sector Perform Rating	MT
24-08-28	Oppenheimer Adjusts MannKind Price Target to $12 From $10, Maintains Outperform Rating	MT
23-11-14	Oppenheimer Adjusts MannKind Price Target to $5.50 From $6.50, Maintains Outperform Rating	MT
23-10-10	Wedbush Initiates MannKind at Outperform With $10 PT; Says Orphan Lung Pipeline Presents Potential for Real Future Value-Creation, Optionality	MT
23-08-14	HC Wainwright Adjusts Price Target on MannKind to $7.50 From $7, Keeps Buy Rating	MT
23-02-27	HC Wainwright Adjusts Price Target on MannKind to $7 From $6, Keeps Buy Rating	MT
22-11-09	SVB Securities Adjusts Price Target on MannKind to $6 From $5, Maintains Outperform Rating	MT
22-02-28	HC Wainwright Trims MannKind's Price Target to $6 From $6.50, Maintains Buy Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	MANNKIND CORPORATION					+141.71%
	ARGENX SE					+22.14%
	WUXI APPTEC CO., LTD.					+41%
	INSMED INCORPORATED					+84.17%
	BIONTECH SE					+40.68%
	WUXI BIOLOGICS (CAYMAN) INC.					+36.6%
	GENMAB A/S					+37.36%
	AKESO, INC.					+43.66%
	SUMMIT THERAPEUTICS INC.					+75.95%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+22.28%
	Average					+54.55%
	Weighted average by Cap.					+42.29%